Zidovudine plus sulfamethoxazole-trimethoprim adversely affects B lymphocyte maturation in bone marrow of normal mice

International Immunopharmacology

Volumn 5, Issue 13-14, 2005, Pages 1881-1894

  Feola, David J ^a   Garvy, Beth A ^b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

AIDS; Apoptosis; B cells; Hematopoiesis; Rodent

Indexed keywords

COTRIMOXAZOLE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BLOOD; BONE MARROW; CELL CYCLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FLOW CYTOMETRY; GRANULOCYTE; IMMUNOCOMPETENT CELL; LUNG; MOUSE; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTI-HIV AGENTS; ANTIGENS, CD43; ANTIGENS, CD45; APOPTOSIS; B-LYMPHOCYTE SUBSETS; BONE MARROW; BONE MARROW CELLS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GRANULOCYTES; IMMUNOPHENOTYPING; ISOANTIGENS; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; SPLEEN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZIDOVUDINE;

EID: 27744481099     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.06.011     Document Type: Article

References (55)

1. P.J. McDonnell, and M.R. Jacobs Hospital admissions resulting from preventable adverse drug reactions Ann Pharmacother 36 2002 1331
2. H.G. Colt, and A.P. Shapiro Drug-induced illness as a cause for admission to a community hospital J Am Geriatr Soc 37 1989 323
3. R.R. Miller Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program Arch Intern Med 134 1974 219
4. D.W. Bates, D.J. Cullen, N. Laird, L.A. Petersen, S.D. Small, and D. Servi Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group JAMA 274 1995 29
5. S.C. Piscitelli, and K.D. Gallicano Interactions among drugs for HIV and opportunistic infections N Engl J Med 344 2001 984
6. R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, A. Meibohm, and J.H. Condra 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine Ann Intern Med 133 2000 35
7. J.S. Montaner, R. Hogg, J. Raboud, R. Harrigan, and M. O'Shaughnessy Antiretroviral treatment in 1998 Lancet 352 1998 1919
8. G. Ippolito, and V. Puro Zidovudine toxicity in uninfected healthcare workers. Italian registry of antiretroviral prophylaxis Am J Med 102 1997 58
9. D.M. Simpson, K.A. Citak, E. Godfrey, J. Godbold, and D.E. Wolfe Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 43 1993 971
10. S. Crowe, D.A. Cooper, and D.E. Chambers Managing HIV: Part 4. Primary therapy. 4.1 Antiretroviral therapies for HIV Med J Aust 164 1996 290
11. R. Yarchoan, R.W. Klecker, K.J. Weinhold, P.D. Markham, H.K. Lyerly, and D.T. Durack Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex Lancet 1 1986 575
12. R.J. McKallip, M. Nagarkatti, and P.S. Nagarkatti Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp120 of human immunodeficiency virus Toxicol Appl Pharmacol 131 1995 53
13. A. Isgro, I. Mezzaroma, A. Aiuti, A. Fantauzzi, M. Pinti, and A. Cossarizza Decreased apoptosis of bone marrow progenitor cells in HIV-1-infected patients during highly active antiretroviral therapy Aids 18 2004 1335
14. J.L. Jones, D.L. Hanson, M.S. Dworkin, D.L. Alderton, P.L. Fleming, and J.E. Kaplan Surveillance for AIDS-defining opportunistic illnesses, 1992-1997 MMWR CDC Surveill Summ 48 1999 1
15. J.E. Kaplan, H. Masur, and K.K. Holmes Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America MMWR Recomm Rep 51 2002 1
16. F.M. Gordin, G.L. Simon, C.B. Wofsy, and J. Mills Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome Ann Intern Med 100 1984 495
17. A.J. van der Ven, P.P. Koopmans, T.B. Vree, and J.W. van der Meer Adverse reactions to co-trimoxazole in HIV infection Lancet 338 1991 431
18. R. Mitsuyasu, J. Groopman, and P. Volberding Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma N Engl J Med 308 1983 1535
19. Y.R. Freund, L. Dousman, J.T. MacGregor, and N. Mohagheghpour Oral treatment with trimethoprim-sulfamethoxazole and zidovudine suppresses murine accessory cell-dependent immune responses Toxicol Sci 55 2000 335
20. R.R. Hardy, C.E. Carmack, S.A. Shinton, J.D. Kemp, and K. Hayakawa Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow J Exp Med 173 1991 1213
21. T.B. Vree, A.J. van der Ven, C.P. Verwey-van Wissen, E.W. van Ewijk-Beneken Kolmer, A.E. Swolfs, and P.M. van Galen Isolation, identification and determination of sulfamethoxazole and its known metabolites in human plasma and urine by high-performance liquid chromatography J Chromatogr B Biomed Appl 658 1994 327
22. P.A. Furman, J.A. Fyfe, M.H. St Clair, K. Weinhold, J.L. Rideout, and G.A. Freeman Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase Proc Natl Acad Sci U S A 83 1986 8333
23. N. Dainiak, M. Worthington, M.A. Riordan, S. Kreczko, and L. Goldman 3′-Azido-3′-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells Br J Haematol 69 1988 299
24. G. Bogliolo, R. Lerza, M. Mencoboni, A. Saviane, and I. Pannacciulli Azidothymidine-induced depression of murine hemopoietic progenitor cells Exp Hematol 16 1988 938
25. A. Foli, F. Benvenuto, G. Piccinini, A. Bareggi, A. Cossarizza, and J. Lisziewicz Direct analysis of mitochondrial toxicity of antiretroviral drugs Aids 15 2001 1687
26. M.G. Zaera, O. Miro, E. Pedrol, A. Soler, M. Picon, and F. Cardellach Mitochondrial involvement in antiretroviral therapy-related lipodystrophy Aids 15 2001 1643
27. P. Rustin Mitochondrial dysfunction in HIV infection: an overview of pathogenesis J HIV Ther 6 2001 4
28. H.C. Cote, Z.L. Brumme, K.J. Craib, C.S. Alexander, B. Wynhoven, and L. Ting Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients N Engl J Med 346 2002 811
29. G. Moyle Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity Clin Ther 22 2000 911
30. M. Barile, D. Valenti, E. Quagliariello, and S. Passarella Mitochondria as cell targets of AZT (zidovudine) Gen Pharmacol 31 1998 531
31. O. Martinez-Maza, E. Crabb, R.T. Mitsuyasu, J.L. Fahey, and J.V. Giorgi Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity J Immunol 138 1987 3720
32. H.C. Lane, H. Masur, L.C. Edgar, G. Whalen, A.H. Rook, and A.S. Fauci Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome N Engl J Med 309 1983 453
33. A.J. Ammann, G. Schiffman, D. Abrams, P. Volberding, J. Ziegler, and M. Conant B-cell immunodeficiency in acquired immune deficiency syndrome JAMA 251 1984 1447
34. M.S. Simberkoff, W. El Sadr, G. Schiffman, and J.J. Rahal Jr. Streptococcus pneumoniae infections and bacteremia in patients with acquired immune deficiency syndrome, with report of a pneumococcal vaccine failure Am Rev Respir Dis 130 1984 1174
35. L.J. Bernstein, H.D. Ochs, R.J. Wedgwood, and A. Rubinstein Defective humoral immunity in pediatric acquired immune deficiency syndrome J Pediatr 107 1985 352
36. J.J. Ballet, G. Sulcebe, L.J. Couderc, F. Danon, C. Rabian, and M. Lathrop Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy Clin Exp Immunol 68 1987 479
37. E.N. Janoff, J.M. Douglas Jr., M. Gabriel, M.J. Blaser, A.J. Davidson, and D.L. Cohn Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1 J Infect Dis 158 1988 983
38. M.R. Dawood, B. Conway, P. Patenaude, F. Janmohamed, J.S. Montaner, and M.V. O'Shaughnessy Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients J Clin Immunol 18 1998 235
39. J.A. Kovacs, J.W. Hiemenz, A.M. Macher, D. Stover, H.W. Murray, and J. Shelhamer Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies Ann Intern Med 100 1984 663
40. A. Carr, B. Tindall, R. Penny, and D.A. Cooper Patterns of multiple-drug hypersensitivities in HIV-infected patients Aids 7 1993 1532
41. D.J. Naisbitt, S.J. Hough, H.J. Gill, M. Pirmohamed, N.R. Kitteringham, and B.K. Park Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity Br J Pharmacol 126 1999 1393
42. R. Buhl, H.A. Jaffe, K.J. Holroyd, F.B. Wells, A. Mastrangeli, and C. Saltini Systemic glutathione deficiency in symptom-free HIV-seropositive individuals Lancet 2 1989 1294
43. A. Carr, C. Swanson, R. Penny, and D.A. Cooper Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS J Infect Dis 167 1993 180
44. A.E. Cribb, M. Miller, J.S. Leeder, J. Hill, and S.P. Spielberg Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity Drug Metab Dispos 19 1991 900
45. A.E. Cribb, and S.P. Spielberg Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine Drug Metab Dispos 18 1990 784
46. J.Y. Chatton, A. Munafo, J.P. Chave, F. Steinhauslin, F. Roch-Ramel, and M.P. Glauser Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide Br J Clin Pharmacol 34 1992 551
47. E. Canas, J. Pachon, F. Garcia-Pesquera, J.R. Castillo, P. Viciana, and J.M. Cisneros Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus Antimicrob Agents Chemother 40 1996 230
48. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J Natl Cancer Inst 92 2000 1295
49. J.D. Schuetz, M.C. Connelly, D. Sun, S.G. Paibir, P.M. Flynn, and R.V. Srinivas MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs Nat Med 5 1999 1048
50. L. Lai, and T.M. Tan Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues Biochem J 361 2002 497
51. J.M. McCune, R. Namikawa, C.C. Shih, L. Rabin, and H. Kaneshima Suppression of HIV infection in AZT-treated SCID-hu mice Science 247 1990 564
52. H. Boxenbaum, and C. DiLea First-time-in-human dose selection: allometric thoughts and perspectives J Clin Pharmacol 35 1995 957
53. I. Mahmood, and J.D. Balian Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species Life Sci 59 1996 579
54. R.C. Hertzberg Fitting a model to categorical response data with application to species extrapolation of toxicity Health Phys 57 Suppl. 1 1989 405
55. J.W. Paxton The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs Clin Exp Pharmacol Physiol 22 1995 851